

# Antonin Schmitt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3895604/publications.pdf>

Version: 2024-02-01

34  
papers

556  
citations

623734

14  
h-index

642732

23  
g-index

39  
all docs

39  
docs citations

39  
times ranked

910  
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 197-208.	2.3	1
2	Lack of everolimus diffusion in pleural fluid during pleural progression of breast cancer: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 235-237.	0.9	2
3	Exposure-response analysis of Raltitrexed assessing liver toxicity. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1327-1337.	2.4	5
4	Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 229-239.	2.3	4
5	Population Pharmacokinetics of Palbociclib in a Real-World Situation. <i>Pharmaceutics</i> , 2021, 14, 181.	3.8	4
6	147P When a single G-CSF administration is better than longer duration: Example in patients treated by eribulin. <i>Annals of Oncology</i> , 2021, 32, S84.	1.2	0
7	Trastuzumab-emtansine induced pleural and pericardial effusions. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522110157.	0.9	3
8	Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation. <i>Annals of Oncology</i> , 2021, 32, 810-811.	1.2	10
9	Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients. <i>Pharmaceutics</i> , 2021, 13, 1708.	4.5	8
10	Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure. <i>Pharmaceutics</i> , 2020, 13, 416.	3.8	11
11	Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2473-2485.	2.4	5
12	Lipoproteins LDL versus HDL as nanocarriers to target either cancer cells or macrophages. <i>JCI Insight</i> , 2020, 5, .	5.0	5
13	A simple and fast LC-MS/MS method for the routine measurement of cabozantinib, olaparib, palbociclib, pazopanib, sorafenib, sunitinib and its main active metabolite in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1132, 121844.	2.3	34
14	Therapeutic drug monitoring as a tool to optimize 5-FU-based chemotherapy in gastrointestinal cancer patients older than 75 years. <i>European Journal of Cancer</i> , 2019, 111, 116-125.	2.8	20
15	ADHERENCE TO ORAL ANTICANCER THERAPIES IN A CLINICAL CANCER CENTRE. <i>Journal of Geriatric Oncology</i> , 2019, 10, S86.	1.0	1
16	Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer. <i>World Journal of Clinical Oncology</i> , 2019, 10, 75-85.	2.3	7
17	Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial. <i>Journal of Hepatology</i> , 2018, 68, 1163-1171.	3.7	15
18	Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: Analyses from 18 trials. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 900-910.	2.4	2

#	ARTICLE	IF	CITATIONS
19	How can we best monitor 5-FU administration to maximize benefit to risk ratio?. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1303-1313.	3.3	33
20	5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer. Oncotarget, 2018, 9, 11559-11571.	1.8	44
21	PS-030 Off-label use of anticancer drugs: Which benefits and how much?. European Journal of Hospital Pharmacy, 2016, 23, A226.3-A227.	1.1	0
22	Improved stability of lipiodol drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin. European Radiology, 2016, 26, 601-609.	4.5	33
23	Idarubicin-Loaded ONCOZENE Drug-Eluting Embolic Agents for Chemoembolization of Hepatocellular Carcinoma: In Vitro Loading and Release and In Vivo Pharmacokinetics. Journal of Vascular and Interventional Radiology, 2015, 26, 262-270.	0.5	29
24	Polymorphisms inSLCO1B3andNR1I2as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination. Pharmacogenomics, 2015, 16, 1439-1450.	1.3	14
25	G-CSF dosing schedule to prevent eribulin-induced neutropenia: Can modelling and simulation help?. Journal of Clinical Oncology, 2015, 33, e20673-e20673.	1.6	1
26	Standardization of chemotherapy and individual dosing of platinum compounds. Anticancer Research, 2014, 34, 465-70.	1.1	6
27	Model-Based Approach to Describe G-CSF Effects in Carboplatin-Treated Cancer Patients. Pharmaceutical Research, 2013, 30, 2795-2807.	3.5	18
28	Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. Cancer Research, 2012, 72, CT-01-CT-01.	0.9	43
29	123 INVITED Application of Population PK-PD Methods in Oncology. European Journal of Cancer, 2011, 47, S30.	2.8	0
30	Factors for Hematopoietic Toxicity of Carboplatin: Refining the Targeting of Carboplatin Systemic Exposure. Journal of Clinical Oncology, 2010, 28, 4568-4574.	1.6	44
31	Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. European Journal of Cancer, 2010, 46, 2763-2770.	2.8	20
32	Factors of interindividual hematopoietic toxicity of carboplatin.. Journal of Clinical Oncology, 2010, 28, 2568-2568.	1.6	0
33	A Universal Formula Based on Cystatin C to Perform Individual Dosing of Carboplatin in Normal Weight, Underweight, and Obese Patients. Clinical Cancer Research, 2009, 15, 3633-3639.	7.0	45
34	Adherence to oral anti-cancer therapies in older patients is similar to that of younger patients. Journal of Oncology Pharmacy Practice, 0, , 107815522211035.	0.9	0